10-Q: Fulgent Genetics Q3 Revenue Jumps 17%, Net Loss Narrows

Fulgent Genetics reported a 17% increase in third-quarter revenue driven by strong growth in precision diagnostics and BioPharma services, while significantly narrowing its net loss.

Summary

• Revenue for the three months ended September 30, 2025, increased by 17% to $84.1 million, up from $71.7 million in the prior year period.
• Net loss attributable to Fulgent significantly narrowed by 55% to $6.6 million in Q3 2025, compared to $14.6 million in Q3 2024.
• Gross profit rose by 33% to $35.5 million in Q3 2025, with gross margin improving to 42% from 37% in the prior year.
• Acquired 100% of ANP Technologies, Inc. on July 9, 2025, for $21.65 million (cash and stock), securing ownership of patents for ongoing clinical studies.
• Recognized a $9.9 million impairment loss on an investment in Helio Genomics, Inc. due to financial deterioration and inability to secure sufficient financing.
• Purchased $33.8 million in Investment Tax Credits (ITCs) for $31.7 million cash during the nine months ended September 30, 2025, with plans to seek a refund by carrying them back to 2021 and 2022 tax years.
• Cash used in operating activities increased significantly to $23.5 million for the nine months ended September 30, 2025, primarily due to the ITC purchase.
• Repurchased $10.9 million of common stock during the nine months ended September 30, 2025, under the $250 million stock repurchase program, with $139.6 million remaining available.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and significantly narrowed its net loss in the quarter, driven by core laboratory services and strategic acquisition. Gross margins improved, and cash position is strong. However, increased cash burn from operating activities (due to tax credit purchases), an impairment loss, and ongoing government investigations and potential FDA delays due to government shutdown present notable headwinds and uncertainties.

Positives

• Strong revenue growth of 17% in Q3 2025 ($84.1 million) and 16% in 9M 2025 ($239.3 million), driven by precision diagnostics (up 16% in Q3), anatomic pathology (up 7% in Q3), and BioPharma services (up 83% in Q3).
• Significant improvement in net loss, narrowing by 55% in Q3 2025 to $6.6 million.
• Gross profit increased by 33% in Q3 2025, with gross margin expanding to 42% from 37%, reflecting streamlined operations and efficiency.
• Successful acquisition of ANP Technologies, Inc., securing critical patents for therapeutic development and aligning with strategic objectives.
• Cash and cash equivalents increased significantly to $117.6 million as of September 30, 2025, from $55.1 million at December 31, 2024.
• Net cash provided by investing activities was $100.2 million for 9M 2025, a substantial improvement from cash used in the prior year.

Negatives

• Net loss attributable to Fulgent for the nine months ended September 30, 2025, slightly worsened to $37.1 million from $36.8 million in the prior year.
• Significant increase in cash used in operating activities, rising to $23.5 million for 9M 2025, primarily due to the purchase of Investment Tax Credits.
• An impairment loss of $9.9 million was recognized on the investment in Helio Genomics, Inc. due to adverse financial conditions.
• Increased operating expenses across research and development (up 18% in Q3), selling and marketing (up 28% in Q3), and general and administrative (up 11% in Q3).
• Revenue from COVID-19 testing services has ceased, with no material future revenues expected.
• Total marketable securities decreased from $773.3 million at December 31, 2024, to $669.9 million at September 30, 2025.

Risks

• Ongoing Civil Investigative Demands (CIDs) from the U.S. Department of Justice (DOJ) under the False Claims Act related to allegations of medically unnecessary laboratory testing, improper billing, and Anti-Kickback/Stark Law violations.
• Subject to an audit by the U.S. Health Resources and Services Administration (HRSA) concerning reimbursement for $548.9 million in COVID-19 tests for uninsured patients, with uncertainty regarding methodology and potential return of reimbursed amounts.
• The current U.S. government shutdown may delay expected IRS tax refunds of approximately $106.7 million and could delay FDA approvals or reviews for therapeutic candidates (FID-007, FID-022).
• One customer accounted for 23% of total revenue in the laboratory services segment for Q3 and 9M 2025, posing a risk if this relationship changes.
• Reliance on a sole supplier for next-generation sequencers and associated reagents, which could interrupt laboratory operations if supply or maintenance is disrupted.
• Major risks and uncertainties associated with the timely and successful completion of development and commercialization of drug candidates, including efficacy confirmation, regulatory approvals, and budgeted costs.
• No assurance that estimates and assumptions for goodwill or in-process research & development (IPR&D) impairment analysis will be accurate, and conclusions could change in future periods.

Future Outlook

Management expects research and development expenses for the therapeutic development segment to continue increasing as clinical trials progress for FID-007, FID-022, and other preclinical studies. The company does not expect future material revenues from COVID-19 testing services. Efforts will focus on increasing the number of customers to reduce revenue concentration risk. The U.S. government shutdown may delay expected IRS tax refunds and FDA approvals for therapeutic candidates.

Management Comments

• "We believe the factors that will affect our ability to grow these revenue streams are 1) the average price point we offer and the reimbursement rate from insurance payors; 2) the concentration of our payor base; 3) the competitive advantage we have due to our broad and flexible test menu, detection rate, and turnaround times; and 4) growth in size of an addressable market."
• "Going forward, we will strive to maintain this competitive advantage and emphasize this in our marketing efforts to grow our testing revenue."
• "To reduce this revenue risk [customer concentration], we will focus on increasing the number of customers and thereby reducing the concentration."
• "We expect research and development expenses for our laboratory services segment to continue to remain consistent for the remainder of 2025."
• "Expenses for our therapeutic development segment will be influenced by our ability to progress our therapeutic candidates through development with the Food and Drug Administration, or the FDA, the timing of which can be uncertain and delayed due to a variety of factors beyond our control, including recently announced staff reductions at the FDA and the effects or residual effects of the current U.S. government shutdown, which may affect the FDAs ability to provide any required approvals or review in a timely manner or in the timelines expected."
• "Looking ahead, we expect research and development expenses to continue increasing as clinical trials progress for FID-007, FID-022, and other preclinical studies."
• "We expect our existing cash, cash equivalents, restricted cash, and short-term marketable securities will continue to be sufficient to meet our anticipated cash requirements for at least the next 12 months."
• "We intend to improve our profitability by improving margins and expanding in new markets for our tests."

Industry Context

Fulgent Genetics is actively transforming from a genomic diagnostic business into a fully integrated precision medicine company, aligning with the broader industry trend towards personalized healthcare and targeted therapies. The acquisition of ANP Technologies strengthens its position in therapeutic development, particularly in cancer treatment, a highly competitive and innovation-driven sector. The company's focus on expanding its laboratory services, including precision diagnostics and BioPharma services, reflects the growing demand for advanced genetic testing and contract research support within the pharmaceutical industry. However, the reliance on a sole supplier for critical lab equipment and reagents is a common vulnerability in specialized biotech sectors, and the ongoing government investigations highlight the intense regulatory scrutiny faced by diagnostic and healthcare service providers.

Legal Proceedings

• Received Civil Investigative Demands (CIDs) from the U.S. Department of Justice (DOJ) under the False Claims Act related to allegations of medically unnecessary laboratory testing, improper billing, and violations of the Anti-Kickback Statute and Stark Law.
• Subject to an audit by the U.S. Health Resources and Services Administration (HRSA) regarding reimbursement for COVID-19 tests furnished to uninsured patients, with uncertainty regarding methodology and potential for return of reimbursed amounts.
• Received a CID from the DOJ related to the HRSA Uninsured Program, investigating whether false claims were submitted.
• Cannot currently predict the resolution, outcome, or potential material adverse impact of these matters, and no liability has been recorded.

Related Party Transactions

• Prior to April 25, 2025, Ming Hsieh (CEO and Chairperson) was on the board and an approximately 20% owner of ANP Technologies, Inc., with which the Company had drug-related licensing and development service agreements.
• Ray Yin (CEO of Fulgent Pharma) is the Founder, President, and CTO of ANP.
• The Company incurred $0.6 million in related party expenses for licensing and development services with ANP for the nine months ended September 30, 2025 (prior to April 25, 2025), and $1.6 million for the nine months ended September 30, 2024.
• As of April 25, 2025, the Company owed ANP $0.3 million.
• The acquisition of ANP in July 2025 included the settlement of all outstanding liabilities and receivables between the parties.

Stakeholder Impact

• Shareholders: Potential for dilution if future capital raises involve equity issuance; benefits from stock repurchase program; uncertainty from legal proceedings and potential FDA delays could impact share price.
• Employees: Increased headcount in cost of revenue and selling and marketing suggests growth in employment; equity-based compensation is a significant component of compensation.
• Customers: Continued focus on competitive advantage through broad testing menu, detection rate, and turnaround times; efforts to diversify customer base to reduce concentration risk.
• Suppliers: High reliance on a sole supplier for critical laboratory equipment and reagents poses a supply chain risk.
• Creditors: Strong cash position and sufficient liquidity for the next 12 months reduce immediate credit risk; notes payable are manageable.

Next Steps

• Progress clinical trials for therapeutic candidates FID-007 and FID-022.
• Continue preclinical studies for other therapeutic candidates.
• Focus on increasing the number of customers to reduce revenue concentration risk.
• Evaluate the potential impact of the One Big Beautiful Bill Act (OBBBA) on future periods.
• Monitor investments for changes in facts and circumstances that may indicate further impairments or observable price changes.
• File a request for a refund for the purchased Investment Tax Credits by carrying them back to the 2021 and 2022 tax years.

Key Dates

Recommendation

While Fulgent Genetics demonstrated strong revenue growth and improved profitability in its core laboratory services, the therapeutic development segment is still in early stages with increasing R&D costs and regulatory uncertainties. The acquisition of ANP is a strategic positive, but the significant ongoing government investigations and audits, coupled with the potential for delays from the U.S. government shutdown, introduce considerable risk. The company's strong cash position and stock repurchase program provide some stability, but the unresolved legal and regulatory matters and reliance on a sole supplier warrant a cautious 'hold' stance until there is greater clarity on these material risks.

Keywords

genetics, precision medicine, cancer therapeutics, laboratory services, genomic diagnostics, SEC filing, 10-Q, biopharma, anatomic pathology, clinical trials, FID-007, FID-022, ANP Technologies, investment tax credits, government shutdown, DOJ investigation, HRSA audit, stock repurchase